MyCare Oncology Products

MyCare by Saladax

MyImatinib*

Targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.

*Product available with CE Mark and RUO

Clinical Information

Imatinib Plasma Levels

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. Demetri GD, Wang Y, Wehrle E, et al. J Clin [...]

Plasma Exposure of Imatinib

Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial.  Guilhot F, Hughes TP, Cortes J, et al. Haematologica. [...]

Imatinib Pharmacokinetics

Imatinib pharmacokinetics and its correlation with response plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity [...]

Trough Imatinib Plasma Levels

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Picard S, Titier K, Etienne G, et al. Blood. [...]

Request Laboratory Info

Fill out my online form
MyCare by Saladax

My5-FU*

BSA dosing results in sub-target 5-FU levels in the majority of patients. PK- guided dosing can move 5-FU levels into the target range. Optimal dosing of 5-FU is associated with increased efficacy and reduced toxicity.

•    Personalize dose to personalize medicine
•    Reduce the risk of under dosing
•    Optimize each individual patient’s dose based on their drug level
•    Potentially improve outcomes with PK-guided dose adjustment.

*Product available with CE Mark and RUO

Clinical Information

Individual Fluorouracil Dose Adjustment

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal [...]

Prospective, multi-center study of 5-FU

Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice.Wilhelm M, Mueller [...]

Therapeutic drug monitoring of 5-fluorouracil

Therapeutic drug monitoring of 5-fluorouracil.   Lee JJ, Beumer JH, Chu E. Cancer Chemother Pharmacol. 2016 78(3):447-464. Review. This very recent and through review concluded: “Dose adjustment [...]

Request Laboratory Info

 

Fill out my online form
MyCare by Saladax

MyPaclitaxel*

Neutropenia and neuropathy can be serious side-effects associated with paclitaxel chemotherapy. While hematological toxicities can be addressed, there is no good solution for chemotherapy induced peripheral neuropathy, which is frequent, may be debilitating and can persist or appear after treatment.

Recent TDM studies ever demonstrated the potential of paclitaxel dose optimization to:

  • Reduce neuropathy
  • Reduce neutropenia
  • Reduce without impacting survival

*Product available with CE Mark and RUO

Clinical Information

Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in advanced Non-Small Cell Lung Cancer (NSCLC)

Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in advanced Non-Small Cell Lung Cancer (NSCLC) Ann [...]

Request Laboratory Info

Fill out my online form
MyCare by Saladax

MyDocetaxel*

Several studies have suggested a relationship between docetaxel pharmacokinetics and pharmaco dynamics. In particular the docetaxel pharmacokinetic parameter Area Under the Curve (AUC) has been associated with the risk of neutropenia and outcomes.

*Product available with CE Mark and RUO

Clinical Information

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer Bruno R, Hille D, Riva A, et al. J Clin Oncol. 1998;16:187-96 This study demonstrated that it [...]

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose Kenmotsu H, Tanigawara Y. Cancer Sci. 2015;106:497-504 This review details studies in the [...]

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study Engels FK, Loos WJ, van der Bol JM, et al. Clin Cancer Res. 2011;17:353-62 High and [...]

Request Laboratory Info

Fill out my online form

+1 (610) 419-6731

hello@saladax.com

Start typing and press Enter to search